Matt Krusen brings over a decade of commercial leadership in biomanufacturing, with deep expertise across gene and cell therapy platforms. Before joining Electron Bio, he held senior roles at Aldevron, where he led client development and strategic alliances supporting global therapeutic programs in plasmid DNA, mRNA, and viral vector production. Throughout his career, Matt has worked at the intersection of science and business, helping biopharma partners navigate the complex landscape of manufacturing scale-up, regulatory requirements, and CMC planning.

At Electron Bio, Matt leads business development and strategic partnerships, supporting the company’s digital-first, biomanufacturing-focused platform. His experience across commercial strategy and GMP operations positions him to accelerate client programs and advance the company’s mission to deliver faster, smarter solutions for modern therapeutics.

Matt holds an M.S. in Biochemistry and Integrated Biomedical Science, with a focus in Infectious Disease, from the University of Notre Dame.